MedTrace Logo

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

NCT06369155 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-03-02

No results posted yet for this study

Summary

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma.

The name of the study drug involved in this study is:

-Azenosertib (a type of Wee1 inhibitor)

Conditions

  • Uterine Serous Carcinoma
  • Uterine Carcinoma
  • Uterine Cancer

Interventions

DRUG

Azenosertib

Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Zentalis

    collaborator UNKNOWN

  • Joyce Liu, MD

    lead OTHER

Principal Investigators

  • Joyce Liu, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-05
Primary Completion
2027-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06369155 on ClinicalTrials.gov